The impact of immunotherapy on overall survival in patients with brain metastases


  • Immunotherapy in combination with radiotherapy increased overall survival (OS) for patients with solid cancers and brain metastases who had received definitive surgery at the primary tumor site.

Why this matters ?

  • In the setting of brain metastasis, the median survival time ranges from 4 to 16 months depending on primary tumor type.

  • Monoclonal antibody immunotherapies are a promising treatment for brain metastases, due to their ability to cross the blood–brain barrier; however, in-depth studies of immunotherapies has been limited so far.

  • It was hypothesized that patients with brain metastases who had received primary tumor resection, thereby having had the bulk of tumor mass removed, would respond better to immunotherapies.

International Medical Press is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.

No responsibility is assumed by International Medical Press for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, International Medical Press recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of International Medical Press or the sponsor. International Medical Press assumes no liability for any material contained herein.